SLCO2B1

Solute carrier organic anion transporter family member 2B1 · O94956 · SLCO2B1 on Sugi Atlas →

24,876 patent compounds predicted against SLCO2B1, 20,321 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Quercetagetin (SCHEMBL554527)	0.72	5/20
Apigenin (SCHEMBL19428)	1.00	4/20
Quercetin (SCHEMBL19723)	1.00	4/20
Quercitrin (SCHEMBL117644)	1.00	4/20
Quercetin (SCHEMBL118425)	1.00	4/20
Quercitrin (SCHEMBL147092)	1.00	4/20
Quercitrin (SCHEMBL147093)	1.00	4/20
Prunin (SCHEMBL318229)	1.00	4/20
Prunin (SCHEMBL318230)	1.00	4/20
Quercetin (SCHEMBL288466)	0.92	4/20
Quercetin (SCHEMBL111510)	0.76	4/20
Robustaflavone (SCHEMBL561807)	0.70	4/20
Hinokiflavone (SCHEMBL617272)	0.70	4/20
SCHEMBL181107	0.70	4/20
SCHEMBL311856	0.67	4/20
SCHEMBL345223	0.66	4/20
Quercetin (SCHEMBL220351)	0.63	4/20
Robustaflavone (SCHEMBL624405)	0.62	4/20
SCHEMBL311728	0.48	4/20
Kaempferol (SCHEMBL18817)	1.00	3/20

Clinical trials — most relevant to SLCO2B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
The Interaction of Herbs and Statins	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM	PHASE1	COMPLETED
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study	EARLY_PHASE1	NOT_YET_RECRUITING
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871	nan	COMPLETED
The Furosemide Stress Test, Electrolytes Response and Renal Index in Critically Ill Patients	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Integrating Pharmacogenetics In Clinical Care	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLCO2B1 binder may also engage these)

Protein	Name	Similarity
Q9JHI3	—	1.000	Q9JHI3 →
Q8BXB6	—	0.997	Q8BXB6 →
Q9EPT5	—	0.987	Q9EPT5 →
SLCO2A1	Solute carrier organic anion transporter family member 2A1	0.986	landscape →
Q99N01	—	0.983	Q99N01 →
Q00910	—	0.978	Q00910 →
Q8K078	—	0.976	Q8K078 →
Q8BPX9	—	0.970	Q8BPX9 →
O08966	—	0.968	O08966 →
Q96BD0	—	0.965	Q96BD0 →
G8XYX6	—	0.965	G8XYX6 →
Q863T6	—	0.964	Q863T6 →
P46720	—	0.964	P46720 →
Q9UIG8	—	0.964	Q9UIG8 →
Q924V4	—	0.963	Q924V4 →
Q99N02	—	0.962	Q99N02 →
Q8IY34	—	0.961	Q8IY34 →
Q9BY10	—	0.961	Q9BY10 →
O77504	—	0.961	O77504 →
Q9ERB5	—	0.961	Q9ERB5 →
P58355	—	0.960	P58355 →
O70324	—	0.960	O70324 →
A7MBE0	—	0.959	A7MBE0 →
Q8MJI6	—	0.959	Q8MJI6 →
Q3UEZ8	—	0.959	Q3UEZ8 →
Q8K1P8	—	0.958	Q8K1P8 →
Q9UMX9	—	0.958	Q9UMX9 →
Q866G7	—	0.958	Q866G7 →
Q4LE88	—	0.958	Q4LE88 →
Q14CH1	—	0.958	Q14CH1 →